Loading...
Chiasma, Inc.
CHMA•NASDAQ
HealthcareBiotechnology
$3.76
$-0.24(-6.00%)
Chiasma, Inc. (CHMA) Stock Overview
Explore Chiasma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CHMAStats details for CHMA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CHMAAnalyst Recommendations details for CHMA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
CEO
Mr. Raj Kannan
Employees
84
Headquarters
140 Kendrick Street, Building C East, Needham, MASSACHUSETTS
Founded
2015